SLC29A1 and cancer: In addition, hENT1 inhibition and, thus, impaired nucleoside uptake was observed upon treatment with the C-Jun N-terminal kinase (JNK) inhibitor JNK-IN-8 in pancreatic cancer cells demonstrating another potential drug class to target pyrimidine salvage in cancer (Figure 2A,D) [70].